Format

Send to

Choose Destination
Semin Oncol. 2005 Dec;32(6 Suppl 8):5-6.

Brief communication: a new combination in the treatment of advanced pancreatic cancer.

Author information

1
Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada. malcolm.moore@uhn.on.ca

Abstract

Single-agent gemcitabine is currently the standard treatment for advanced pancreatic cancer. A majority of recent phase III trials have shown either marginal or no improvement in survival using gemcitabine in combination with other chemotherapeutic and novel agents. Our group recently reported that the combination of gemcitabine with erlotinib was associated with a significant prolongation of survival and improvement in progression-free survival in advanced pancreatic cancer.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center